ArticlePathogens (Basel, Switzerland)2014
Wild mushroom extracts as inhibitors of bacterial biofilm formation.
Article in Pathogens (Basel, Switzerland), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 58 citations in OpenAlex.
- Eco-friendly optimization and green biosynthesis of Cu(II) nanocomposites from Stereum ostrea biomass extract: enhanced antibiofilm efficacy against pathogenic bacteria.Discover nano · 2026Article
- The Dual Role of the Medicinal MushroomFood science & nutrition · 2025Article
- Unveiling the Bioactive Compounds and Therapeutic Potential ofJournal of fungi (Basel, Switzerland) · 2025Review
- Bioprospecting Bioactive Peptides inMarine drugs · 2025Article
- Bioluminescent Whole-Cell Bioreporter Bacterial Panel for Sustainable Screening and Discovery of Bioactive Compounds Derived from Mushrooms.Biosensors · 2024Article
- Biofilm-Inhibitory Activity of Wild Mushroom Extracts against Pathogenic Bacteria.Evidence-based complementary and alternative medicine : eCAM · 2024Article
- Artificial Neural Network Prediction of Antiadhesion and Antibiofilm-Forming Effects of Antimicrobial Active Mushroom Extracts on Food-Borne Pathogens.Antibiotics (Basel, Switzerland) · 2023Article
- A Comparative Study ofJournal of fungi (Basel, Switzerland) · 2023Article
- Wild Mushrooms: Potential Natural Sources of Antioxidant and Anti-Quorum Sensing Bioactive Compounds for Medical Applications.Evidence-based complementary and alternative medicine : eCAM · 2023Article
- Wild Mushrooms: A Hidden Treasure of Novel Bioactive Compounds.International journal of analytical chemistry · 2023Article
- Mycopharmaceuticals and Nutraceuticals: Promising Agents to Improve Human Well-Being and Life Quality.Journal of fungi (Basel, Switzerland) · 2021Review
- Challenges of antibiotic resistance biofilms and potential combating strategies: a review.3 Biotech · 2021Review
- Bioactive Phytochemical Constituents of Wild Edible Mushrooms from Southeast Asia.Molecules (Basel, Switzerland) · 2020Review
- Food Safety through Natural Antimicrobials.Antibiotics (Basel, Switzerland) · 2019Review
- Challenges of intervention, treatment, and antibiotic resistance of biofilm-forming microorganisms.Heliyon · 2019Review
- Genetic diversity of Lepista nuda (Agaricales, Basidiomycota) in Northeast China as indicated by SRAP and ISSR markers.PloS one · 2018Article
- Antibiofilm activity and bioactive phenolic compounds of ethanol extract from theJournal of advanced pharmaceutical technology & researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microorganisms can colonize a wide variety of medical devices, putting patients in risk for local and systemic infectious complications, including local-site infections, catheter-related bloodstream infections, and endocarditis. These microorganisms are able to grow adhered to almost every surface, forming architecturally complex communities termed biofilms. The use of natural products has been extremely successful in the discovery of new medicine, and mushrooms could be a source of natural antimicrobials. The present study reports the capacity of wild mushroom extracts to inhibit in vitro biofilm formation by multi-resistant bacteria. Four Gram-negative bacteria biofilm producers (Escherichia coli, Proteus mirabilis, Pseudomonas aeruginosa, and Acinetobacter baumannii) isolated from urine were used to verify the activity of Russula delica, Fistulina hepatica, Mycena rosea, Leucopaxilus giganteus, and Lepista nuda extracts. The results obtained showed that all tested mushroom extracts presented some extent of inhibition of biofilm production. Pseudomonas aeruginosa was the microorganism with the highest capacity of biofilm production, being also the most susceptible to the extracts inhibition capacity (equal or higher than 50%). Among the five tested extracts against E. coli, Leucopaxillus giganteus (47.8%) and Mycenas rosea (44.8%) presented the highest inhibition of biofilm formation. The extracts exhibiting the highest inhibitory effect upon P. mirabilis biofilm formation were Sarcodon imbricatus (45.4%) and Russula delica (53.1%). Acinetobacter baumannii was the microorganism with the lowest susceptibility to mushroom extracts inhibitory effect on biofilm production (highest inhibition-almost 29%, by Russula delica extract). This is a pioneer study since, as far as we know, there are no reports on the inhibition of biofilm production by the studied mushroom extracts and in particular against multi-resistant clinical isolates; nevertheless, other studies are required to elucidate the mechanism of action.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.